Eczema in early childhood is strongly associated with the development of asthma and rhinitis in a prospective cohort

Laura B von Kobyletzki1,2*, Carl-Gustaf Bornehaq2, Mikael Hasselgren3,4, Malin Larsson2, Cecilia Boman Lindström2 and Åke Svensson1

Abstract

Background: This study aimed to estimate the association between eczema in early childhood and the onset of asthma and rhinitis later in life in children.

Methods: A total of 3,124 children aged 1–2 years were included in the Dampness in Building and Health (DBH) study in the year 2000, and followed up 5 years later by a parental questionnaire based on an International Study of Asthma and Allergies in Childhood protocol. The association between eczema in early childhood and the incidence of asthma and rhinitis later in life was estimated by univariable and multivariable logistic regression modelling.

Results: The prevalence of eczema in children aged 1–2 years was 17.6% at baseline. Children with eczema had a 3-fold increased odds of developing asthma (adjusted odds ratio [aOR], 3.07; 95% confidence interval (CI) 1.79–5.27), and a nearly 3-fold increased odds of developing rhinitis (aOR, 2.63; 1.85–3.73) at follow-up compared with children without eczema, adjusted for age, sex, parental allergic disease, parental smoking, length of breastfeeding, site of living, polyvinylchloride flooring material, and concomitant allergic disease. When eczema was divided into subgroups, moderate to severe eczema (aOR, 3.56; 1.62–7.83 and aOR, 3.87; 2.37–6.33, respectively), early onset of eczema (aOR, 3.44; 1.94–6.09 and aOR, 4.05; 2.82–5.81; respectively), and persistence of eczema (aOR, 5.16; 2.62–10.18 and aOR, 4.00; 2.53–6.22, respectively) further increased the odds of developing asthma and rhinitis. Further independent risk factors increasing the odds of developing asthma were a parental history of allergic disease (aOR, 1.83; 1.29–2.60) and a period of breast feeding shorter than 6 months (aOR, 1.57; 1.03–2.39). The incidence of rhinitis was increased for parental history of allergic disease (aOR, 2.00; 1.59–2.51) and polyvinylchloride flooring (aOR, 1.60; 1.02–2.51).

Conclusion: Eczema in infancy is associated with development of asthma and rhinitis during the following 5-year period, and eczema is one of the strongest risk factors. Early identification is valuable for prediction of the atopic march.

Background

The prevalence of eczema has increased to levels of public health relevance in the Western world, especially in children [1]. As the most frequent inflammatory condition in childhood, eczema affects physiological and psychological wellbeing of affected children and results in substantial costs [2,3]. It has been suggested that early life eczema is a risk factor for the development of asthma later in life [4]. However, evidence for the progression to asthma comes mainly from cross-sectional studies [5]. There are only a few prospective cohort studies that have investigated the association between early life eczema and later onset of asthma and rhinitis [6–11]. Some of the existing longitudinal studies found no association between eczema and later onset of asthma [6–8], and other prospective studies found an eczema/asthma relationship much weaker than expected.
Methods

Data collection

The methods of the population-based Swedish Dampness in Buildings and Health (DBH) study have been published by Bornehag et al. and Larsson et al. [15,16].

The DBH study started in 2000, and a questionnaire based on an International Study of Asthma and Allergies in Childhood (ISAAC) protocol [17] was given to parents of all children aged 1 to 5 years living in the county of Värmland (DBH-I). Follow-up was performed in 2005 in children who were aged 1 to 3 years in 2000 (DBH-III). In this study we investigated the children initially aged 1–2 years.

Four thousand and twenty children initially aged 1–2 years had answered a baseline questionnaire in 2000 based on an ISAAC protocol. The cohort of the current study consisted of 3,124 children who responded both to the baseline and a follow-up questionnaire in 2005 (response rate: 77.7%).

Inclusion criteria of the baseline survey were all children living in Värmland aged 1–5 years whose parents gave consent to participate and who answered a postal questionnaire. The study was approved by the regional ethical committee in Örebro.

Definition of variables

The original ISAAC questions were used. In addition, questions on doctor-diagnosed asthma and doctor-diagnosed rhinitis were included. The additional questions were: “Has your child been diagnosed with asthma by a physician?” and “Has your child been diagnosed with rhinitis by a physician?” The main outcomes were “5-year cumulative incidence of asthma” and “5-year cumulative incidence of rhinitis”. The “5-year cumulative incidence of asthma” was defined as no report of physician-diagnosed asthma and no wheezing at baseline in 2000, but physician-diagnosed asthma was reported in 2005. The “5-year cumulative incidence of rhinitis” was defined as no report of physician-diagnosed rhinitis in 2000, but physician-diagnosed rhinitis was reported in 2005.

The main explanatory variable was eczema. Eczema in early childhood was defined by affirmative responses to the question “Has your child had an itchy rash at any time in the last 12 months?” in the baseline questionnaire in 2000.

Secondary analysis was performed for subgroups of eczema, persistent eczema, severe eczema and early onset of eczema, and their association with later development of allergic airway diseases. Persistent eczema was assumed when children reported signs of eczema both at baseline and at follow-up; the questions asked were: “Has your child ever had an itchy rash (eczema) which was coming and going for at least 6 months?” and “Has your child had this itchy rash at any time in the last 12 months?” in 2000, and “Has your child had this itchy rash at any time in the last 12 months?” in 2005. The onset of eczema was determined form the question “At what age did this itchy rash first occur?” in 2000, and it was categorised into “early onset” if symptoms occurred before the age of 1 year. The question “In the last 12 months, how often, on average, has your child been kept awake at night by eczema?” was included in the ISAAC eczema questionnaire as a measure of the severity of eczema, where sleep loss several times per week was considered to be severe eczema [17,18]. To simplify analysis, the severity of eczema was re-categorized, by using “any awakening at night” as an identifier for moderate to severe eczema, and “no awakening” was considered to be mild eczema. Information on single parenthood was obtained via the question “How many adults are currently living with the child”; two adults caring for the child could be any two adults.

Statistical analysis

The association between eczema in early childhood and the development of asthma and rhinitis was estimated by using univariable logistic regression and expressed as odds ratios (ORs) with confidence intervals (CIs). Statistical significance was assessed using the likelihood ratio test (LRT; p < 0.05). Characteristics of participants and non-participants were compared in drop-out analysis using the chi-square test (p < 0.05). Crude analysis of the association between all other risk factors, and asthma and rhinitis were performed. Linear trends of variables with several categories were evaluated. In multivariable logistic regression analysis, the ORs were adjusted for sex, age of the child, socioeconomic variables (parental smoking, number of adults living with the child, and type of house), and potential confounding variables, which included all other factors (see Table 1). The potential confounding variables were added in descending order of strength of crude association (smallest p-value first). Factors still associated with asthma and rhinitis were kept in the model. The interaction between
Table 1 Crude associations between risk factors at baseline and the incidence of asthma and rhinitis*

| Risk factor at baseline | Total number in category n (%) | Number with asthma n | Asthma OR (95% CI) | P-value | Number with rhinitis n | Rhinitis OR (95% CI) | P-value |
|-------------------------|--------------------------------|----------------------|---------------------|---------|------------------------|----------------------|---------|
| Eczema                  |                                |                      |                     |         |                        |                      |         |
| No                      | 2,573 (82.4)                  | 101                  | 1.0                 | <0.001  | 107                    | 1.0                  | <0.001  |
| Yes                     | 551 (17.6)                    | 49                   | 2.85 (1.72-4.71)    | 0.001   | 65                     | 3.14 (2.27-4.36)     | 0.001   |
| Persistence of eczema   |                                |                      |                     |         |                        |                      |         |
| No                      | 2,886 (92.4)                  | 58                   | 1.0                 | <0.001  | 135                    | 1.0                  | 0.001   |
| Yes                     | 238 (7.6)                     | 15                   | 4.20 (2.31-7.64)    | 0.001   | 37                     | 3.92 (2.64-5.82)     | 0.001   |
| Onset of eczema         |                                |                      |                     |         |                        |                      |         |
| No                      | 2,483 (80.6)                  | 46                   | 1.0                 | <0.001  | 98                     | 1.0                  | <0.001  |
| Age ≥ one year          | 216 (6.9)                     | 6                    | 1.87 (0.7-4.45)     | 0.46    | 85                     | 0.96 (0.46-2.00)     | 0.96    |
| Age < one year          | 386 (12.6)                    | 21                   | 3.63 (2.12-6.22)    | 0.50    | 66                     | 5.02 (3.58-7.05)     | 0.50    |
| Eczema severity         |                                |                      |                     |         |                        |                      |         |
| No                      | 2,478 (79.47)                 | 45                   | 1.0                 | <0.001  | 98                     | 1.0                  | <0.001  |
| Mild                    | 468 (15.0)                    | 17                   | 2.42 (1.36-4.29)    | 0.74    | 47                     | 2.74 (1.90-3.95)     | 0.74    |
| Moderate to severe      | 173 (5.5)                     | 11                   | 4.55 (2.27-9.12)    | 0.75    | 27                     | 4.74 (2.98-7.55)     | 0.75    |
| Gender                  |                                |                      |                     |         |                        |                      |         |
| Female                  | 1,546 (49.5)                  | 25                   | 1.0                 | 0.002   | 65                     | 1.0                  | 0.002   |
| Male                    | 1,579 (50.5)                  | 48                   | 2.16 (1.32-3.54)    | 0.01    | 107                    | 1.67 (1.21-2.29)     | 0.01    |
| Age of the child        |                                |                      |                     |         |                        |                      |         |
| 12-23 month             | 1,557 (49.8)                  | 41                   | 1.0                 | 0.325   | 88                     | 1.0                  | 0.325   |
| 24-35 month             | 1,568 (50.2)                  | 32                   | 0.79 (0.49-1.27)    | 0.95    | 84                     | 0.95 (0.70-1.29)     | 0.95    |
| Parental history of allergic disease | | |<0.001>| |<0.001>| |
| No parent               | 1,594 (51.0)                  | 26                   | 1.0                 | <0.001  | 47                     | 1.0                  | <0.001  |
| One parent              | 1,199 (38.4)                  | 32                   | 1.92 (1.14-3.25)    | 0.25    | 83                     | 2.45 (1.69-3.53)     | 0.25    |
| Two parents             | 332 (10.6)                    | 15                   | 3.67 (1.90-7.08)    | 0.01    | 42                     | 4.85 (3.12-7.55)     | 0.01    |
| Asthma in the child     |                                |                      |                     |         |                        |                      |         |
| No                      | 2,843 (91.4)                  | –                    | –                   | –       | 147                    | 1.0                  | <0.001  |
| Yes                     | 269 (8.6)                     | –                    | –                   | –       | 25                     | 4.10 (2.57-6.54)     | 0.791   |
| Length of breastfeeding |                                |                      |                     |         |                        |                      |         |
| Longer than 6 month     | 2,043 (65.9)                  | 44                   | 1.0                 | 0.021   | 112                    | 1.0                  | 0.021   |
| Up to 6 months          | 974 (31.4)                    | 23                   | 1.14 (0.68-1.90)    | 0.73    | 54                     | 1.02 (0.73-1.43)     | 0.73    |
| No breastfeeding        | 82 (2.7)                      | 6                    | 3.32 (1.36-8.11)    | 0.57    | 6                      | 1.35 (0.57-3.16)     | 0.57    |
| Number of bedrooms with PVC |                              |                      |                     |         |                        |                      |         |
| No PVC in bedroom       | 1,300 (42.8)                  | 23                   | 1.0                 | 0.184   | 60                     | 1.0                  | 0.184   |
| PVC in one bedroom      | 558 (18.4)                    | 14                   | 1.42 (0.72-2.79)    | 0.99    | 38                     | 1.51 (0.99-2.30)     | 0.99    |
| PVC in two bedrooms     | 1,183 (38.9)                  | 34                   | 1.65 (0.96-2.82)    | 0.92    | 70                     | 1.31 (0.92-1.87)     | 0.92    |
| Type of building        |                                |                      |                     |         |                        |                      |         |
| Single-family house     | 2,522 (82.4)                  | 58                   | 1.0                 | 0.902   | 137                    | 1.0                  | 0.902   |
| Multi-family house      | 538 (17.6)                    | 12                   | 1.04 (0.55-1.96)    | 0.75    | 33                     | 1.13 (0.75-1.70)     | 0.75    |
| Parental smoking        |                                |                      |                     |         |                        |                      |         |
| No                      | 2,431 (77.8)                  | 56                   | 1.0                 | 0.691   | 139                    | 1.0                  | 0.691   |
| Yes                     | 694 (22.2)                    | 17                   | 1.12 (0.64-1.94)    | 0.83    | 33                     | 0.83 (0.56-1.23)     | 0.83    |
eczema and sex was explored. The effect of different subgroups of eczema on asthma and rhinitis was examined. Because of the strong association between persistence, early onset and severe eczema, three adjusted models for these groups are reported.

Clustering by families was considered. No clustering effects were found after statistical assessment. The results obtained using robust standard errors, generalised estimating equations, and random effect modelling were similar to those obtained from the analysis of single subjects in terms of the exposure outcome relationship, and no evidence for significant intra-cluster correlation was found. Therefore, ordinary logistic regression models are shown that ignore clustering. The Hosmer and Lemeshow goodness-of-fit test statistic provided evidence that the models were a good fit to the data [19]. We undertook a sensitivity analysis and used questions that asked about symptoms of asthma/rhinitis (wheezing and runny nose) and questions that asked about doctors’ diagnoses (asthma and rhinitis). This was performed in case people’s perceptions of symptoms are stronger indications of health than reports of doctors’ diagnoses.

Drop out in the study
Of 4,020 children aged 1–2 years, who participated in the baseline survey in 2000, 3,124 children participated in the follow-up in 2005. A total of 896 children did not continue participating in the study. There were no differences in background (age and sex) and health factors (prevalence of eczema, asthma, wheezing and rhinitis, and parents with history of allergic disease) measured at baseline between the children participating in both surveys compared with the “drop-outs” (p > 0.05). However, there was a higher prevalence of socioeconomic risk factors, parental smoking (30.5% vs. 22.2%; p < 0.001), one adult living with a child (11.1% vs. 6.2%; p < 0.001), and living in a multifamily house (27.0% vs. 17.6%; p < 0.001) in drop-outs compared with that in participants.

Odds of developing asthma and rhinitis
Unadjusted analyses showed that children with eczema at baseline had more than a 2-fold increase in the odds of developing asthma (OR, 2.85; 95% CI, 1.72–4.71) and a 3-fold increase in the odds of developing rhinitis (OR, 3.14; 2.27–4.36) compared with children without eczema at baseline. The odds for developing asthma and rhinitis remained increased after adjustment (aOR, 3.07; 1.79–5.27 and aOR, 2.63; 1.85–3.73, respectively) for eczema, sex, age, family history of allergic disease, asthma, length of breastfeeding, PVC-flooring material in the home, type of building, environmental tobacco smoke, and number of adults living in the child (Table 2).

Different subgroups of children with eczema
In adjusted analysis, children with persistence of eczema, early onset of eczema, or moderate to severe eczema had even higher odds of developing asthma and rhinitis than children with eczema in general. The odds of developing asthma and rhinitis was 5-fold in children with persistence of eczema compared with the absence of eczema (aOR, 5.16; 2.62–10.18 and aOR, 4.00; 2.53–6.22, respectively). Early onset of eczema was a strong risk factor for the incidence of asthma (aOR, 3.44; 95% CI, 1.94–6.09) and the incidence of rhinitis (aOR, 4.05; 95% CI, 2.82–5.81) compared with children without eczema, whereas there was no significant
association between the late onset of eczema and the incidence of asthma (aOR, 2.07; 0.78–5.49) and rhinitis (aOR, 0.96; 0.45–2.03). Both mild and moderate to severe eczema were associated with the incidence of asthma and rhinitis compared with children without eczema, with a higher odds of developing asthma and rhinitis in moderate to severe eczema (aOR, 3.56; 1.62–7.83 and aOR, 3.87; 2.37–6.33, respectively) than mild eczema compared with children without eczema (aOR, 2.85; 1.57–5.19 and aOR, 2.37; 1.60–3.51, respectively) (Table 3).

Other risk factors for development of asthma and rhinitis during a 5-year period

In adjusted analysis, a parental history of allergic disease increased the odds of developing asthma and rhinitis by 2-fold. The odds of developing asthma was 2-fold and that of developing rhinitis was 59% higher in boys...
compared with girls. Further, asthma increased the odds of developing rhinitis by nearly 3-fold, and a period of breastfeeding shorter than 6 months increased the risk of developing asthma by 57% (Table 2). PVC-flooring material in the bedroom increased the incidence of asthma and rhinitis, but statistical significance was only reached for the relationship between PVC flooring-material and rhinitis. Interestingly, PVC-flooring material had a higher effect on girls for the incidence of asthma and rhinitis in all models (data not shown).

Interactions between eczema and sex were explored and there was no effect of eczema on the incidence of asthma and rhinitis across sex strata (interaction p-values: 0.747 for asthma and 0.664 for rhinitis).

Sensitivity analysis
For assessing the relationships between asthma and rhinitis and remission, we used different assessments of asthma and rhinitis to ensure that the relationship was stable and not dependent on which questions were used. We used both reports of symptoms and reports of doctors’ diagnoses. Both of these reports were similar in both crude and adjusted analysis; eczema increased the odds of developing rhinitis symptoms (OR, 2.81; 2.23–3.55 and aOR, 2.39; 1.86–3.08) and wheezing symptoms (OR, 2.10; 1.37–3.23 and aOR, 1.97; 1.24–3.12).

Discussion
Our study found that eczema in early childhood was strongly associated with the development of asthma and rhinitis during the following 5-year period. Eczema was one of the strongest independent risk factors. Interestingly, when eczema was divided into subgroups, children with early onset of eczema, moderate to severe eczema, and persistence of eczema had the highest odds of developing asthma and rhinitis.

Table 3 Subgroups of eczema in children and the 5-year cumulative incidence of asthma and rhinitis

| Eczema group                        | Crude OR (95% CI) | P-value | Adjusted OR* (95% CI) | P-value |
|-------------------------------------|-------------------|---------|-----------------------|---------|
| **Incidence of asthma (N = 2063)**  |                    |         |                       |         |
| Duration of eczema                  |                    |         |                       |         |
| Never eczema                        | 1.0               | <0.001  | 1.0                   | <0.001  |
| Eczema only in 2000                 | 1.94 (0.93-4.06)  | <0.001  | 2.17 (1.01-4.65)      | <0.001  |
| Eczema only in 2005                 | 1.97 (0.94-4.13)  | 1.77 (0.77-4.11) |
| Persistence of eczema**             | 4.95 (2.65-9.25)  | 5.16 (2.62-10.18) |
| Onset of eczema                     |                    |         |                       |         |
| Late onset of eczema**              | 1.87 (0.78-4.45)  | <0.001  | 2.07 (0.78-5.49)      | <0.001  |
| Early onset of eczema **            | 3.63 (2.12-6.22)  |         | 3.44 (1.94-6.09)      |         |
| Severity of eczema                  |                    |         |                       |         |
| Mild eczema***                      | 2.42 (1.36-4.29)  | <0.001  | 2.85 (1.57-5.19)      | <0.001  |
| Moderate to severe eczema**         | 4.55 (2.27-9.11)  |         | 3.56 (1.62-7.83)      |         |
| **Incidence of rhinitis (N = 2751)**|                    |         |                       |         |
| Duration of eczema                  |                    |         |                       |         |
| No eczema                           | 1.0               | <0.001  | 1.0                   | <0.001  |
| Eczema only in 2000                 | 2.52 (1.61-3.94)  | 2.25 (1.40-3.61) |
| Eczema only in 2005                 | 1.96 (1.20-3.21)  | 2.00 (1.19-3.37) |
| Persistence of eczema**             | 4.91 (2.33-7.46)  | 4.00 (2.53-6.22) |
| Onset of eczema                     |                    |         |                       |         |
| Late onset of eczema**              | 0.96 (0.46-2.00)  | <0.001  | 0.96 (0.45-2.03)      | <0.001  |
| Early onset of eczema **            | 5.02 (3.58-7.05)  |         | 4.05 (2.82-5.81)      |         |
| Severity of eczema                  |                    |         |                       |         |
| Mild eczema***                      | 2.74 (1.90-3.95)  | <0.001  | 2.37 (1.60-3.51)      | <0.001  |
| Moderate to severe eczema**         | 4.74 (2.98-7.55)  |         | 3.87 (2.37-6.33)      |         |

* If not otherwise stated, the comparisons are dichotomous with the referent category being the low-odds group (aOR = 1), and the high-odds group data shown in the table.
** Adjustments were made for gender, age, family history of allergic disease, asthma, length of breastfeeding, PVC-flooring material in the home, type of building, environmental tobacco smoke, and number of adults living with the child.
### Defined as eczema ever for at least 6 months, and current eczema in both 2000 and 2005.
#### no eczema in 2000 as reference.
This population-based prospective study confirms that early eczema affects later development of asthma and rhinitis.

Although some previous prospective studies were not able to show an association between early childhood eczema and later development of asthma and rhinitis [6,8], our findings are robust and in line with the study by Arshad et al. [9]. In addition, similar results regarding severity have been found in both Gustavsson's and Ricci's eczema cohorts [12,13], which reported that eczematous children with high severity scores were at increased risk of developing asthma. To the best of our knowledge, our study is the first prospective cohort to show that early onset of eczema or persistent eczema increases the odds of later onset of asthma in both boys and girls, which is in contrast to a previous study that only showed a relationship in boys [20]. Definitions of asthma and rhinitis are important for the interpretation of results [15]. Our sensitivity analysis confirmed that the association between eczema and asthma/rhinitis remained when symptom-based criteria for asthma and rhinitis were used.

Possible explanations for the relationship between eczema and asthma and rhinitis

Evidence from several experimental studies has suggested that impaired epithelial function results in increased sensitization and IgE production [21]. In humans, the theory of epicutaneous sensitization is supported by the observation that exposing atopic children to topical emollients containing peanut protein leads to an increased risk of airway peanut sensitization [22]. Genetic factors, such as the common loss of function mutations within the filaggrin gene, are a risk factor for incident eczema and account for skin barrier dysfunction [23,24]. Recently, it has been shown that filaggrin mutations affect asthma, which supports the hypothesis that impaired skin function acts as a gateway for allergens, increasing the risk of atopic airways diseases [25].

Advantages and limitations

A major advantage of our study was its prospective design, which made results less subject to recall bias and allowed assessment of temporal relationships. Our study had a large sample size compared with earlier studies [6,8]. Our results should be less prone to selection and ascertainment bias because of its population-based design. We also had a high response rate and limited loss to follow-up. There were no differences between the analysed sample and drop-outs in health-related variables; therefore, results might have been biased towards 1. A higher prevalence of socioeconomic risk factors in children leaving the study, while assuming that low socioeconomic status is a risk factor for the incidence of asthma, might have biased the results towards 1 as well. Therefore, our conclusions that eczema is associated with later onset of asthma and rhinitis would not change if all children had participated. The advantages of the study design and performance allow generalization of results.

Reporting of eczema by questionnaire might have advantages compared with assessment by physicians, because eczema can be intermittent [26]. The term “itchy flexural rash in the last 12 months” has been shown to correlate well with diagnosis by a physician in a validation study performed in the UK on children aged 3–11 years [18]. Sensitivity in this previous study was 84% and specificity was 93% [18]. In addition, the ISAAC eczema questionnaire has been used for studies on pre-school children [26]. Although questions for diagnosis have been validated for eczema in 4–11-year-olds and for asthma in children aged 1–6 years [27], the ISAAC questionnaire has not been validated for parental information regarding pre-school children. However, we consider that it is unlikely that there was differential misclassification; random misclassification would mean that any bias in our estimates was towards null.

Currently, there is no clear definition of persistence of eczema, which is consistent as reported by Williams [28]. Illi [7] and Möhrenschilder [29] considered eczema as persistent when signs of the disease were present at different points of time. In our study, persistence of eczema was defined as having had eczema at least three times. Therefore, the risk of including children with “short-term rashes only” might be low, but we cannot exclude the possibility that some children classified as having persistent eczema had longer symptom-free intervals. It would have been advantageous to assess the prevalence of eczema more often during the study period.

Implications

Based on the results of our study, further evidence is required to unravel the underlying mechanisms of eczema in early childhood leading to asthma. Although we confirmed a relationship between childhood eczema and incident asthma and rhinitis, the association between childhood eczema and later asthma and rhinitis might still be separate and sequential, but are otherwise unrelated in the background of an atopic phenotype. Because the relationship between childhood eczema and incident asthma and rhinitis was temporal, strong, and linear, our findings suggest that the relationship might be causal. In this regard, impaired skin function might hypothetically be one explanatory factor [21], and the effect of early and successful treatment of eczema should be explored regarding the incidence of asthma as one outcome measure [30,31]. Further, it might be beneficial to
estimate if objective measured sensitization (IgE) modifies or confounds the eczema/asthma relationship in future studies. Our study results have important implications for patient management since asthma can lead to high impairment and costs.

Conclusions
Eczema in infancy independently increases the odds of developing asthma and rhinitis during the following 5-year period. This association is present for children with eczema at baseline; however when they are divided into subgroups (severe eczema, early onset of eczema and persistence of eczema) the odds of the incidence of asthma and rhinitis further increases. Identifying risk groups is important for healthcare planning.

Abbreviations
DBHI: Dampness in Building and Health; ISAAC: International Study of Asthma and Allergies in Childhood; PVC: Polyvinyl chloride.

Competing interests
There is no conflict of interest among the authors Laura B. von Kobyletzki, Carl-Gustaf Bornehag, Mikael Hasselgren, Malin Larsson, Cecilia Boman Lindström, and Åke Svensson, between reporting of the study findings, and financial or non-financial interests that might bias the report.

Authors' contributions
LVK, AS and CGB take responsibility for the integrity of the data. LVK drafted the manuscript. AS, CGB, and ML interpreted the data. LVK, AS, and CGB interpreted the data. LVK, AS and CGB take responsibility for the integrity of the data. LVK drafted the manuscript. AS, CGB, MH, ML, LVK, and CBL were involved in acquisition of data. LVK, AS, CGB, and ML interpreted the data. LVK drafted the manuscript. AS, CGB, MH, ML, and CBL critically revised the manuscript for important intellectual content. AS and CGB supervised the study. All authors read and approved the final manuscript.

Author details
1Lund University, Institute of Clinical Research in Malmö, Skåne University Hospital, Department of Dermatology, Malmö, Sweden. 2Karlstad University, Department of Public Health Sciences, Karlstad, Sweden. 3Örebro University, School of Medicine, Örebro, Sweden. 4County Council of Värmland, Primary Care Research Unit, Karlstad, Sweden.

Received: 13 October 2011 Accepted: 16 July 2012 Published: 27 July 2012

References
1. Williams H, Stewart A, von Mutius E, Cookson W, Anderson HR: Is eczema really on the increase worldwide? J Allergy Clin Immunol 2008, 121:947–954.
2. Lewis-Jones S: Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract 2006, 60:984–992.
3. Carroll CL, Balkrishnan R, Feldman SR, Fleischer AB Jr, Manuel JC: The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol 2005, 22:193–199.
4. Spergel JM, Aller AS: Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003, 112:S18–S127.
5. Beasley R, Keil U, von Mutius E, et al: Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet 1998, 351:1225–1232.
6. the Group Health Medical Associates, Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ: Asthma and wheezing in the first six years of life. N Engl J Med 1995, 332:133–138.
7. Illi S, von Mutius E, Lau, S, Nickel R, Gruber C, Niggemann B, et al: The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol 2004, 113:925–931.
8. Klintner MD, Nelson HS, Price VR, Adinoff AD, Leung DY, Mazarik DA: Onset and persistence of childhood asthma: predictors from infancy. Pediatrics 2001, 108:E69.
9. Arshad SH, Kurukulaarachchi RJ, Fenn M, Matthews S: Early life risk factors for current wheeze, asthma, and bronchial hyperresponsiveness at 10 years of age. Chest 2005, 127:502–508.
10. Burgess JA, Dharmage SC, Byrnes GB, Matheson MC, Gurwin LC, Wharton CL, Johns DP, Abramson MJ, Hopper JL, Walters EH: Childhood eczema and asthma incidence and persistence: a cohort study from childhood to middle age. J Allergy Clin Immunol 2008, 122:280–285.
11. Martin PE, Matheson MC, Gurwin L, Burgess JA, Osborne N, Lowe AJ, Morrison S, Mesaros D, Giles GG, Abramson MJ, et al: Childhood eczema and rhinitis predict atopic but not nonatopic adult asthma: a prospective cohort study over 4 decades. J Allergy Clin Immunol 2011, 127:1473–1479, e1471.
12. Ricci G, Patrizi A, Baldi E, Mienna G, Tabanelli M, Masì M: Long-term follow-up of atopic dermatitis: retrospective analysis of related risk factors and association with concomitant allergic diseases. J Am Acad Dermatol 2006, 55:765–771.
13. Gustafsson D, Sjöberg O, Foucard T: Development of allergies and asthma in infants and young children with atopic dermatitis—a prospective follow-up to 7 years of age. Allergy 2000, 55:240–245.
14. Quelle-Roussel C, Raynaud F, Sauvat JH: A prospective computerized study of 500 cases of atopic dermatitis in childhood. I. Initial analysis of 250 parameters. Acta Derm Venereol Suppl (Stockh) 1985, 114:57–92.
15. Larsson M, Lagerhed-Engman L, Sigsgaard T, Janson S, Sundell J, Bornehag CG: Incidence rates of asthma, rhinitis and eczema symptoms and influential factors in young children in Sweden. Acta Paediatr 2008, 97:1210–1215.
16. Bornehag CG, Sundell J, Sigsgaard T: Dampness in buildings and health (DBHI): Report from an ongoing epidemiological investigation on the association between indoor environmental factors and health effects among children in Sweden. Indoor Air 2004, 14(Suppl 7):59–66.
17. Asher MI, Keil U, Anderson HR, Beasley R, Crane J, Martinez F, et al: International Study of Asthma and Allergies in Childhood (ISAAC): rationale and methods. Eur Respir J. 1995, 8:483–491.
18. Williams H, Robertson C, Stewart A, Att-Khaled N, Anabwani G, Anderson R, et al: Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol 1999, 103:125–138.
19. Lemeshow S, Hosmer DW Jr: A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol 1982, 116:92–106.
20. Lowe AJ, Carlin JB, Bennett CM, Hosking CS, Abramson MJ, Hill DJ, et al: Do boys do the atopic march while girls dwarf? J Allergy Clin Immunol 2008, 121:1190–1195.
21. Kolarik B, Naydenov K, Larsson M, Bornehag CG, Sundell J: The association between phthalates in dust and allergic diseases among Bulgarian children. Environ Health Perspect 2008, 116:98–103.
22. Cookson W: The immunogenetics of asthma and eczema: a new focus on the epithelium. Nat Rev Immunol 2004, 4:978–988.
23. Weidinger S, Illig T, Baurrecht H: Loss-of-function variations within the flaggir gene predispose for atopic dermatitis with allergic sensitizations. J Allergy Clin Immunol 2006, 118:214–219.
24. Weidinger S, O’Sullivan M, Illig T: Flaggir mutations, atopic eczema, hay fever, and asthma in children. J Allergy Clin Immunol 2008, 121:1203–1209.
25. Lack G, Fox D, Northstone K, Golding J: Factors associated with the development of peanut allergy in childhood. N Engl J Med 2003, 348:977–985.
26. Peroni DG, Pacentini GL, Alfonsi L, Zerman L, Di Blasi P, Visona G, et al: Rhinitis in pre-school children: prevalence, association with allergic diseases and risk factors. Clin Exp Allergy 2003, 33:1349–1354.
27. Hederos C-A, Hasselgren M, Hedlin G, Bornehag CG: Comparison of clinically diagnosed asthma with parental assessment of children’s asthma in a questionnaire. Pediatr Allergy Immunol 2007, 18:135–141.
28. Williams HC: Atopic dermatitis: the epidemiology, causes and prevention of atopic eczema. Cambridge: Cambridge University Press; 2000.
29. Mohrenschlager M, Schafer T, Huss-Marp J, Ebefelt-Koning B, Weidinger S, Ring J, et al: The course of eczema in children aged 5–7 years and its relation to atopy: differences between boys and girls. Br J Dermatol 2006, 154:505–513.
30. Brown SJ, Asai Y, Cordell HJ, Campbell LE, Zhao Y, Liao H, et al: Loss-of-function variants in the filaggrin gene are a significant risk factor for peanut allergy. *J Allergy Clin Immunol* 2011, 127:661–667.

31. Simpson EL, Berry TM, Brown PA, Hanifin JM: A pilot study of emollient therapy for the primary prevention of atopic dermatitis. *J Am Acad Dermatol* 2010, 63:S87–S93.

doi:10.1186/1471-5945-12-11

Cite this article as: von Kobyletzki et al: Eczema in early childhood is strongly associated with the development of asthma and rhinitis in a prospective cohort. *BMC Dermatology* 2012 12:11.